Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non - small-cell lung cancer
Carcinoma, Non-Small-Cell Lung
Short-duration pazopanib was generally well tolerated and demonstrated single-agent activity in patients with early-stage NSCLC. Several target genes were dysregulated after pazopanib treatment, validating target-specific response and indicating a persistent pazopanib effect on lung cancer tissue. Further clinical evaluation of pazopanib in NSCLC is planned.